Broken redirects

Jump to navigation Jump to search

The following redirects link to non-existent pages:

Showing below up to 50 results in range #2,281 to #2,330.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Better to be a pear than an apple: new prospective look at associations between fat distribution and coronary heart disease → Special:Badtitle/NS100:Better to be a pear than an apple: new prospective look at associations between fat distribution and coronary heart disease
  2. Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS Trial → Special:Badtitle/NS100:Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS Trial
  3. Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial → Special:Badtitle/NS100:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial
  4. Bivalirudin is no better than heparin in patients pretreated with clopidogrel undergoing PCI: Results from the ISAR-REACT-3 trial → Special:Badtitle/NS100:Bivalirudin is no better than heparin in patients pretreated with clopidogrel undergoing PCI: Results from the ISAR-REACT-3 trial
  5. Cardiac Resynchronization Therapy and Single Center Experience Links Survival → Special:Badtitle/NS100:Cardiac Resynchronization Therapy and Single Center Experience Links Survival
  6. Cardiac arrest during weekends and nights is associated with poor outcomes → Special:Badtitle/NS100:Cardiac arrest during weekends and nights is associated with poor outcomes
  7. Cardiogenic Shock: New Treatment Options with Percutaneous Left Ventricular Assist Devices? → Special:Badtitle/NS100:Cardiogenic Shock: New Treatment Options with Percutaneous Left Ventricular Assist Devices?
  8. Cardiologists’ Use of Pulmonary Artery Catheter Information in CCU Treatment Decisions → Special:Badtitle/NS100:Cardiologists’ Use of Pulmonary Artery Catheter Information in CCU Treatment Decisions
  9. Cardiovascular risk increases with incremental doses of celecoxib → Special:Badtitle/NS100:Cardiovascular risk increases with incremental doses of celecoxib
  10. Changes in Residents’ Hours of Work Not Generally Reflected in Improved Outcomes → Special:Badtitle/NS100:Changes in Residents’ Hours of Work Not Generally Reflected in Improved Outcomes
  11. Clinical Research Organizations (CROs), Academic Research Organizations (AROs), or Industry: Who’s best for clinical research → Special:Badtitle/NS100:Clinical Research Organizations (CROs), Academic Research Organizations (AROs), or Industry: Who’s best for clinical research
  12. Clinical data support the non-inferiority of continuous chest compressions compared with conventional cardiopulmonary resuscitation → Special:Badtitle/NS100:Clinical data support the non-inferiority of continuous chest compressions compared with conventional cardiopulmonary resuscitation
  13. Clot retrieval from the coronary arteries during primary angioplasty improves myocardial perfusion and clinical outcomes → Special:Badtitle/NS100:Clot retrieval from the coronary arteries during primary angioplasty improves myocardial perfusion and clinical outcomes
  14. CoStar Drug Eluting Stent is not Non-inferior to TAXUS Drug Eluting Stents → Special:Badtitle/NS100:CoStar Drug Eluting Stent is not Non-inferior to TAXUS Drug Eluting Stents
  15. Cocoa Containing Flavanols might be Beneficial in Diabetic Patients with Vascular Dysfunction → Special:Badtitle/NS100:Cocoa Containing Flavanols might be Beneficial in Diabetic Patients with Vascular Dysfunction
  16. Coronary Calcium Coverage Score is Associated with an Increase in the Risk of Coronary Artery Disease → Special:Badtitle/NS100:Coronary Calcium Coverage Score is Associated with an Increase in the Risk of Coronary Artery Disease
  17. Coronary heart disease mortality in young women makes the headline news → Special:Badtitle/NS100:Coronary heart disease mortality in young women makes the headline news
  18. Culotte is better than crush for bifurcation lesions: Results from the Nordic Stent Technique study → Special:Badtitle/NS100:Culotte is better than crush for bifurcation lesions: Results from the Nordic Stent Technique study
  19. Cyclosporine Reduces Reperfusion Injury and Infarct Size Following Acute Myocardial Infarction → Special:Badtitle/NS100:Cyclosporine Reduces Reperfusion Injury and Infarct Size Following Acute Myocardial Infarction
  20. Darapladib A Direct Lipoprotein Associated Phospholipase A2 Inhibitor Reduces Necrotic Core but not Plaque Deformability → Special:Badtitle/NS100:Darapladib A Direct Lipoprotein Associated Phospholipase A2 Inhibitor Reduces Necrotic Core but not Plaque Deformability
  21. Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure → Special:Badtitle/NS100:Data from ADHERE: BNP and Troponin are independent predictors of in-hospital mortality in patients with decompensated heart failure
  22. Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction → Special:Badtitle/NS100:Defribillators: Systematic Review of ICDs for Adults with LV Systolic Dysfunction
  23. Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control → Special:Badtitle/NS100:Diabetes Care Makes an "ADVANCE" with Better Blood Pressure Control
  24. Diagnosing Heart Failure in the Emergency Department → Special:Badtitle/NS100:Diagnosing Heart Failure in the Emergency Department
  25. Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007 → Special:Badtitle/NS100:Door-to-Ballon Time less than 90 Minutes is Achievable and Sustainable: the Geisinger experience. August 12, 2007
  26. Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter → Special:Badtitle/NS100:Dronedarone (Multaq®) a Promising New Drug for the Management of Patients with Atrial Fibrillation or Flutter
  27. Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES) → Special:Badtitle/NS100:Drug-Eluting Stents: Meta-analysis Demonstrates Superior Clinical Performance of Sirolimus-eluting Stents (SES) Over Bare-metal Stents (BMS) and Paclitaxel-eluting Stents (PES)
  28. Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization → Special:Badtitle/NS100:Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization
  29. Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents → Special:Badtitle/NS100:Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents
  30. Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES → Special:Badtitle/NS100:Drug eluting stents: GRACE Analysis Shows Five Times Higher Mortality Rate Between Six Months and Two Years Among Patients Receivng DES
  31. Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years → Special:Badtitle/NS100:Drug eluting stents are associated with reduced mortality in patients with myocardial infarction at two years
  32. Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial → Special:Badtitle/NS100:Dual therapy better than monotherapy to treat hypertension in the ACCOMPLISH trial
  33. Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide → Special:Badtitle/NS100:Duke Research Teams Provide Insight into Small Vessels, Stored Blood, and Nitric Oxide
  34. Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study → Special:Badtitle/NS100:Early Transfer of AMI Patients for PCI improves cardiovascular outcomes in the TRANSFER-AMI study
  35. Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel → Special:Badtitle/NS100:Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel
  36. Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina → Special:Badtitle/NS100:Elevated microalbuminuria within the “normal-range” predicts mortality in patients with stable angina
  37. Emergency Medical Services Remain Underutilized in STEMI Patients → Special:Badtitle/NS100:Emergency Medical Services Remain Underutilized in STEMI Patients
  38. Eptifibatide: Result of EVA-AMI Trial Released → Special:Badtitle/NS100:Eptifibatide: Result of EVA-AMI Trial Released
  39. Eptifibatide: Results of BRIEF-PCI Trial Released → Special:Badtitle/NS100:Eptifibatide: Results of BRIEF-PCI Trial Released
  40. Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients → Special:Badtitle/NS100:Erectile dysfunction is associated with adverse cardiovascular events among diabetic patients
  41. Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience → Special:Badtitle/NS100:Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience
  42. Excel biodegradable stents are safe and effective: Results from the CREATE trial → Special:Badtitle/NS100:Excel biodegradable stents are safe and effective: Results from the CREATE trial
  43. ExoSeal® Vascular Closure Device is safe and effective → Special:Badtitle/NS100:ExoSeal® Vascular Closure Device is safe and effective
  44. Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection → Special:Badtitle/NS100:Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection
  45. Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI → Special:Badtitle/NS100:Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI
  46. Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis → Special:Badtitle/NS100:Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis
  47. F.I.R.E. Study Misses Primary Endpoint → Special:Badtitle/NS100:F.I.R.E. Study Misses Primary Endpoint
  48. FDA Advisors Under Review for the Potential of Financial Conflict. August 8, 2007 → Special:Badtitle/NS100:FDA Advisors Under Review for the Potential of Financial Conflict
  49. FDA Panel Recommends Approval of New DES → Special:Badtitle/NS100:FDA Panel Recommends Approval of New DES
  50. FDA Requires Stronger Heart Failure Warning for Avandia and Actos → Special:Badtitle/NS100:FDA Requires Stronger Heart Failure Warning for Avandia and Actos

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://www.wikidoc.org/index.php/Special:BrokenRedirects"